Phase 3 Start

RLMD: Phase3_Start: A Phase 3 Study Evaluating the Efficacy and Safety of NDV-01 in Participants With Non-muscle Invasive Bladder Cancer (RESCUE)

Name: Phase3_Start: A Phase 3 Study Evaluating the Efficacy and Safety of NDV-01 in Participants With Non-muscle Invasive Bladder Cancer (RESCUE)
Start: 2027-02-01
End: 2027-02-01

February 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: February 1, 2027
Company: RELMADA THERAPEUTICS, INC. (RLMD)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Start

Phase3_Start: A Phase 3 Study Evaluating the Efficacy and Safety of NDV-01 in Participants With Non-muscle Invasive Bladder Cancer (RESCUE)

February 1, 2027

RLMD overview →

Company: RELMADA THERAPEUTICS, INC. (RLMD)